With Alhemo (concizumab-mtci) from Novo Nordisk A/S, a third hemophilia drug in the past eight months has been approved by the U.S. FDA. The once-daily injectable prophylaxis is to prevent or reduce ...

The approval of concizumab-mtci (Alhemo) injection marks a significant milestone in managing hemophilia A and B with ...

The FDA recently approved the treatment by Novo Nordisk for hemophilia A or B with inhibitors, designed to prevent or reduce ...

Explore the investment prospects of 2seventy Bio, a spin-off from bluebird bio, in the competitive field of cell therapies ...

Undeterred by last year’s rejection and the recent approval of a close rival from Pfizer, Novo Nordisk has pushed its ...

Promising early results from an ongoing randomized, open-label, single-arm, Phase 3 study could pave the way for a Pfizer ...

The Food and Drug Administration (FDA) has approved Alhemo ® (concizumab-mtci) injection for routine prophylaxis to prevent or reduce the frequency of bleeding episodes in adult and pediatric patients ...

Novo Nordisk (NVO) wins U.S. FDA nod for its Alhemo injection as a once-daily prophylaxis for bleeding prevention in patients ...

The U.S. Food and Drug Administration has approved Novo Nordisk's drug for the prevention or reduction of bleeding episodes ...

Chad Stevens of Newdale, Idaho, is infused with a gene therapy for hemophilia B at the Nebraska Medical Center in mid-October ...

A staff member at the Nebraska Medical Center prepares to infuse Idaho resident Chad Stevens with a gene therapy for ...

Altuviiio (efanesoctocog alfa) may work better than other treatments as a hemophilia A factor replacement therapy, a study ...